Skip to main content

PDX Models Market | Growing at a CAGR of 16.7%

Market Growth Analysis:
The global PDX models market is expected to reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of 16.7%. The growth of the overall Patient Derived Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251

Objectives Of Study:
1. To define, describe, and measure the global Patient Derived Xenograft (PDX) models market by model type, tumor type, application, end user, and region

2. To provide detailed information regarding the major factors, such as drivers, restraints, growth opportunities, and challenges influencing the growth of the market

3. To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the global PDX models market

Growing Application Driving Growth In PDX Models Market:

In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251

Key Players in PDX Models Market:

The various players in the global PDX models industry include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
Labels:

Comments

Post a Comment

Popular posts from this blog

Best Accounting Software to Kick-start the Business for Smaller Firms – Xero

  Xero Accounting Software is an online software mainly designed for the accounting needs of small business firms. The software can be operated from a PC, phone, tablet, or Mac to view the cash flows of the company in real-time. The software is for small business houses and hence it is simple to use yet smart so that the users can devote most of the time in other important areas of their business. USP of This Software: Xero accounting software offers accounting services to small business firms in a smarter way. Some of the USPs of the software the more than 800apps integrated into the software, secure encryption, support system better performance report generation, and others apart from the basic accounting services offered. Best Accounting Software for Medium-Sized Businesses@ https://blog.360quadrants.com/2020/best-accounting-software-for-medium-sized-businesses/ Xero Pricing Xero accounting software offers 30 days of free trial after which you can choose from any of the pri...
Post a Comment
Read more

Cell Sorting Market

The global  cell sorting market  is projected to reach USD 247.4 Million by 2021, at a CAGR of 7.0% in the forecast period (2016-2021). Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of global Market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of market. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and RoW. Among the four geographic regions, North America is estimated to command the largest share of the market in 2016, foll...
Post a Comment
Read more

Risk-based Monitoring Software Market | Key Factor in Clinical Trial | Market Growth Worth $511 million

  Growth in the risk based monitoring software market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials. However, the high implementation cost of RBM solutions is expected to restrain the growth of this market during the forecast period. RBM Software Market Dynamics: Impact Analysis 1. Increased outsourcing of clinical trial processes to CROs 2. Cost and time efficiency of RBM solutions 3. Increasing government funding and grants to support clinical trials 4. Increased pharmaceutical R&D spending 5. Initiatives to boost digital health to propel market growth The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429 Software Component: The sof...
Post a Comment
Read more